- Home
- KXIN vs GRI Comparison
KXIN vs GRI Comparison
Compare KXIN & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- GRI
- Stock Information
- Founded
- KXIN 2015
- GRI 2018
- Country
- KXIN China
- GRI United States
- Employees
- KXIN N/A
- GRI N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- KXIN Consumer Discretionary
- GRI Health Care
- Exchange
- KXIN Nasdaq
- GRI Nasdaq
- Market Cap
- KXIN 3.0M
- GRI 3.0M
- IPO Year
- KXIN N/A
- GRI N/A
- Fundamental
- Price
- KXIN $2.60
- GRI $0.77
- Analyst Decision
- KXIN
- GRI Strong Buy
- Analyst Count
- KXIN 0
- GRI 1
- Target Price
- KXIN N/A
- GRI $12.00
- AVG Volume (30 Days)
- KXIN 3.0M
- GRI 9.9M
- Earning Date
- KXIN 01-01-0001
- GRI 11-14-2024
- Dividend Yield
- KXIN N/A
- GRI N/A
- EPS Growth
- KXIN N/A
- GRI N/A
- EPS
- KXIN N/A
- GRI N/A
- Revenue
- KXIN $12,679,000.00
- GRI N/A
- Revenue This Year
- KXIN N/A
- GRI N/A
- Revenue Next Year
- KXIN N/A
- GRI N/A
- P/E Ratio
- KXIN N/A
- GRI N/A
- Revenue Growth
- KXIN N/A
- GRI N/A
- 52 Week Low
- KXIN $2.28
- GRI $0.30
- 52 Week High
- KXIN $148.86
- GRI $106.29
- Technical
- Relative Strength Index (RSI)
- KXIN 38.07
- GRI 49.32
- Support Level
- KXIN $2.80
- GRI $0.79
- Resistance Level
- KXIN $7.30
- GRI $1.00
- Average True Range (ATR)
- KXIN 0.86
- GRI 0.17
- MACD
- KXIN -0.09
- GRI -0.02
- Stochastic Oscillator
- KXIN 6.37
- GRI 24.95
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company primarily generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.